Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy

Retina

Volumn 29, Issue 9, 2009, Pages 1213-1217

  Lima, Luiz H ^a,b   Zweifel, Sandrine A ^a,b   Engelbert, Michael ^a,b   Sorenson, John A ^a,b   Slakter, Jason S ^a,b   Cooney, Michael J ^a,b   Klancnik, James M ^a,b   Yannuzzi, Lawrence A ^a,b   Freund, K Bailey ^a,b  

^a VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

^b EAR AND THROAT HOSPITAL   (United States)

Author keywords

Antivascular endothelial growth factor; Bevacizumab; Complications; Intravitreal injection; Ranibizumab

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

AGED; ARTICLE; BACTERIUM CULTURE; CASE REPORT; DRUG SAFETY; ENDOPHTHALMITIS; EVALUATION; EYE INFLAMMATION; FEMALE; HUMAN; INCIDENCE; MALE; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; FEMALE; FUNCTIONAL LATERALITY; HUMANS; INCIDENCE; INJECTIONS; MACULAR DEGENERATION; MALE; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCAL INFECTIONS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRIDANS STREPTOCOCCI; VISUAL ACUITY; VITREOUS BODY;

EID: 70350141504     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181b32d27     Document Type: Article

References (19)

1. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
2. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113:363-372.
3. Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 2008;16:791-799.
4. Rodriguez-Fontal M, Alfaro V, Kerrison JB, Jablon EP. Ranibizumab for diabetic retinopathy. Curr Diabetes Rev 2009;5:47-51.
5. Silva RM, Ruiz-Moreno JM, Nascimento J, et al. Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 2008;28:1117-1123.
6. Lommatzsch A, Spital G, Trieschmann M, Pauleikhoff D. Intraocular application of bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks. Ophthalmologe 2007;104:325-328.
7. Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol 2006;90:1542-1547.
8. Eskens FA, Sleijfer S. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit? Eur J Cancer 2008;44:2350-2356.
9. Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Macular Photocoagulation Study Group. Arch Ophthalmol 1993;111:1189-1199.
10. Gragoudas ES, Adamis AP, Cunnigham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular agerelated macular degeneration. N Engl J Med 2004;351:2805-2816.
11. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57- 65.e5.
12. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008; 145:879-882.
13. Wickremasinghe SS, Michalova K, Gilhotra J, et al. Acute intraocular inflammation after intravitreous injection of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 2008;115:1911-1915.
14. Mamalis N, Edelhauser HF, Dawson DG, Chew J, LeBoyer RM, Werner L. Toxic anterior segment syndrome. J Cataract Refract Surg 2006;32:324-333.
15. Savelkoul HF, Vossen AC, Breedland EG, Tibbe GJ. Semipreparative purification and validation of monoclonal antibodies for immunotherapy in mice. J Immunol Methods 1994;172: 33-42.
16. Meyer CH, Ziemssen F, Heimann H. Intravitreal injection. Monitoring to avoid postoperative complications. Ophthalmologe 2008;105:143-155.
17. Jonas JB, Spandau UH, Rensch F, Von Baltz S, Schlichtenbrede F. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther 2007;23: 240-242.
18. Ta CN, Egbert PR, Singh K, Shriver EM, Blumenkranz MS, Miño De Kaspar H. Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacine prophylaxis for cataract surgery. Ophthalmology 2002;109:2036-2041.
19. Isenberg SJ, Apt L, Yoshimori R, Pham C, Lam NK. Efficacy of topical povidone-iodine during the first week after ophthalmic surgery. Am J Ophthalmol 1997;124:31-35.